CCL22 and colorectal adenocarcinoma: In melanoma, CCL22 boosts Treg recruitment into the TME while inhibiting anticancer immunity (49) and in colorectal adenocarcinomas, CCL22 mRNA expression is considerably higher in tumor tissue than in corresponding normal tissue (50).